<DOC>
	<DOCNO>NCT00867854</DOCNO>
	<brief_summary>This laboratory-based sub-study ATN 061 ATN 071 examine effect early treatment follow treatment de-intensification atazanavir/ritonavir ( ATV/r ) monotherapy steady-state frequency replication-competent CD4+ T cell Human Immunodeficiency Virus ( HIV ) -1 reservoirs cell-associated infectivity ( CAI ) persistent low-level viremia ( LLV ) , contribution successful long-term control HIV-1 replication among HIV-1 infect adolescent young adult .</brief_summary>
	<brief_title>Treatment De-Intensification Residual HIV-1 Youth</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>081 participant must first enrol either ATN 061 ATN 071 meet eligibility criterion protocols addition . 061 Participants Currently treatment ATV/rbased HAART regimen ( ATV/r , FTC , TDF prefer regimen ) ; HIV1 viral load &lt; 100 copy week 24 ; CD4+ T cell count &gt; 350 cells/mm3 week 24 ; Able provide inform consent substudy adhere protocol . 071 Participants Initiated HAART accord current DHHS guideline ( CD4+ T cell &lt; 350 cells/ mm3 ) ; Currently treatment PIcontaining HAART regimen ; subject take protease inhibitor OTHER ATV/r must receive approval team via ATN QNS ; Plasma HIV1 viral load &lt; 100 copy week 24 HAART ; measurement collect clinical care result contain medical record clinical site within +/ 30 day week 24 therapy ; CD4+ T cell count &gt; 350 cells/mm3 week 24 HAART ; measurement collect clinical care result contain medical record clinical site within +/ 30 day week 24 therapy ; Able provide inform consent substudy adhere protocol . General Currently enrol Standard Care Arm ATN 061 ; Pregnancy breast feeding ; Severe ( Grade â‰¥ 3 ) anemia condition would allow adequate blood volume drawn ; Active treatment systemic infection ; Treatment immune modulators , include immunosuppressive immune modulate therapy ( IL2 , intravenous gammaglobulin , therapeutic experimental vaccine include HIV1 vaccine give primary prevention time ( short course ( &lt; 14 day ) prednisone reactive airway disease ( RAD ) permit ) ; Active hepatitis B infection define Hepatitis B antigen ( Ag ) positive ; Disallowed Medications ( see Section 5.3.2 ) ; Active drug alcohol use dependence , opinion site personnel , would interfere adherence study ; History chronic renal insufficiency Grade 3 great serum creatinine . 061Specific Exclusion Criteria History Acquired Immunodeficiency Syndrome ( AIDS ) define illness ; Meets ATN 061 exclusion criterion deintensification ; Meets ATN 061 premature study discontinuation criterion . 071Specific None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>de-intensification</keyword>
	<keyword>HAART</keyword>
	<keyword>monotherapy</keyword>
	<keyword>persistent low-level viremia ( LLV )</keyword>
	<keyword>treatment experience</keyword>
</DOC>